RAMSEY, N.J. and BOCA RATON, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company...
FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income...
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company...
FY 2025 Preliminary Unaudited Total Revenue of Approximately $510–511 Million Meets or Exceeds Prior Guidance Previously Provided FY 2025 Adjusted EBITDA (1) and Adjusted Net Income (2) Guidance...
RAMSEY, N.J. and BOCA RATON, Fla., Jan. 05, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S.-based, end-to-end commercial biopharmaceutical company...
3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase 3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase 3Q 2025 Adjusted EBITDA (1) of $58.7 Million, a 29% YoY Increase...
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company...
ADMA Biologics (ADMA) reported better-than-expected results for the second quarter. Adjusted earnings per share of 15 cents beat the Zacks Consensus Estimate by a penny.Revenues of $122 million (up 14%...